Clinical response, progression-free survival (PFS) and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in Checkmate 069 study Meeting Abstract

  

Authors:	Hodi, F. S.; Postow, M. A.; Chesney, J.; Pavlik, A. C.; Robert, C.; Grossman, K.; McDermott, D.; Linette, G.; Meyer, N.; Giguere, J. K.; Agarwala, S. S.; Shaheen, M.; Ernstoff, M. S.; Minor, D.; Salama, A. K.; Taylor, M.; Ott, P. A.; Horak, C.; Gagnier, P.; Wolchok, J. D.
Abstract Title:	Clinical response, progression-free survival (PFS) and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) versus IPI monotherapy in Checkmate 069 study
Meeting Title:	COSA's 42nd Annual Scientific Meeting
Journal Title:	Asia-Pacific Journal of Clinical Oncology
Volume:	11
Issue:	Suppl. 4
Meeting Dates:	2015 Nov 17-19
Meeting Location:	Hobart, Australia
ISSN:	1743-7555
Publisher:	Wiley Blackwell
Date Published:	2015-11-01
Start Page:	109
Language:	English
ACCESSION:	WOS:000364320800142
PROVIDER:	wos
PUBMED:	26525766
DOI:	10.1111/ajco.12432_2
Notes:	Meeting Abstract: 163 -- SI -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/86175